Inadequate supply-chain practices
The bio/pharmaceutical industry's lack of supply-chain sophistication spans the entire length of the chain, from input sourcing,
through production and inventory management, to distribution. At the front end of the chain, we need only be reminded of the
heparin disaster of a few years ago to appreciate the weaknesses in quality assurance and supplier management for key inputs.
At the distribution end of the supply, the bio/pharmaceutical industry has been under attack regarding counterfeiting and
security of supply. A recent article in Fortune magazine recounted last year's theft of $75 million of finished drug product from an Eli Lilly warehouse in Enfield, Connecticut
(1). The article highlighted the lax security at the warehouse, including failure to monitor security cameras that could have
caught the theft while it was taking place (1).
Supply-chain management weakness also can be seen in the way the industry manages its inventories. On average, the global
bio/pharmaceutical companies turn their inventories a little more than twice a year. They typically have inventory on hand
equivalent to about 180 days' worth of sale. By contrast, a best-practice consumer products firm, such as Procter and Gamble,
turns its inventory about six times a year and has about 60 days' worth of inventory on hand. As global bio/pharmaceutical
companies are trying to maximize their cash-on-hand to help them weather the patent cliff and take advantage of licensing
and acquisition opportunities, keeping so much cash tied up in inventory is a real competitive disadvantage.
Opportunity for contract services
The supply-chain management challenges facing the bio/pharmaceutical industry represent a major opportunity for providers
of contract services, especially those in manufacturing (i.e., contract manufacturing organizations [CMOs]) and packaging.
Because of their critical position relative to both the upstream and downstream segments of the supply-chain, CMOs and packagers
are well positioned to help bio/pharmaceutical companies manage their risk and squeeze cost and inventory out of the system.
We have seen isolated instances of contract services providers responding to supply-chain management opportunity (e.g., Patheon's
recent efforts to promote its services as a backup source of supply and Almac's short-run packaging services). We've also
seen some major providers of third-party logistics services (3PL), such as UPS, DHL and FedEx, make greater efforts to address
the bio/pharmaceutical industry.
However, the big opportunity will come when service providers, especially CMOs, figure out how to increase the flexibility
and responsiveness of their own operations. For instance, every day that a CMO can knock off the manufacturing schedule lock-in
requirement from its traditional three months can save its bio/pharmaceutical company clients millions of dollars in cash
tied up in inventory. Further, the internal process changes necessary to achieve those scheduling improvements are likely
to deliver substantial cost savings and increased throughput. Given that most CMOs operate well below full capacity, such
flexibility should be attainable.
CMOs have traditionally focused on additions to processing technologies, equipment and gain-to-gain incremental volume. Given
the supply-chain challenges facing the bio/pharmaceutical industry, a focus on operations excellence in the context of supply-chain
management is likely to yield greater performance for both the client and CMO and yield market share gains going forward.
Jim Miller is president of PharmSource Information Services, Inc., and publisher of Bio/Pharmaceutical Outsourcing Report, tel. 703.383.4903, fax 703.383.4905, firstname.lastname@example.org
1. K. Eban, Fortune, Mar. 31, 2011, http://features.blogs.fortune.cnn.com/2011/03/31/drug-theft-goes-big/, accessed Apr. 11, 2010.